Business
BioVie Announces “BioVie Day” to be held March 23, 2023
CARSON CITY, Nev., Feb. 21, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative
About this update from Biovie Inc.
[{"type":"text","content":"CARSON CITY, Nev., Feb. 21, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that BioVie Day will be held March 23, 2023 at 10 a.m. Eastern Standard Time. BioVie Day will provide an opportunity for the Company to provide a synthesis of the data released from its clinical trials over the past 6 months. The Company will share an integrated picture of its progress, an overview of the importance of the reported data when taken in totality and announce plans for advancing the various programs towards regulatory registration. BioVie Day will be used to: Present additional data from the Alzheimer’s Disease, Parkinson’s Disease, and Liver Disease programs;Announce details on new clinical trials that will be launched to continue development for the various programs and share thinking on the regulatory paths for getting them filed for registration;Provide guidance on our approach commercialization and collaboration/partnerships;Answer questions from investors and analysts. Registration details and additional data will be announced in the coming weeks as BioVie Day approaches and as the company prepares submissions to a series of scientific conferences over the next 6-9 months. About BioVie BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company’s drug candidate NE3107 inhibits inflammatory activation of ERK and NFkB (e.g., TNF signaling) that leads to neuroinflammation and insulin resistance, but not their homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both are drivers of Alzheimer’s and Parkinson’s diseases. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease (NCT04669028). Results of a Phase 2 investigator initiated trial (NCT05227820) showing NE3107-treated patients experienced improved cognition and biomarker levels were presented at the Clinical Trial in Alzheimer’s Disease ...